This page shows the latest benralizumab news and features for those working in and with pharma, biotech and healthcare.
AZ brought five new medicines to market in 2017 - including new cancer medicines Imfinzi (durvalumab) and Calquence (acalabrutinib) as well as Fasenra (benralizumab) for asthma - and added new indications for Lynparza
Fasenra (benralizumab) is the third IL-5-targetting drug approved for market after GlaxoSmithKline’s Nucala (mepolizumab) and Teva’s Cinqaero (reslizumab) and according to AZ, it is the first biologic
which include AstraZeneca with recently approved Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).
As with the triple, GSK is facing off against AZ in this category as the latter’s Fasenra (benralizumab) IL-5 blocker - recently approved by the FDA - is also in testing
It’s the first approval for Fasenra (benralizumab), as well as the first for AZ’s emerging portfolio of respiratory biologic drugs, and the company says it is taking the marketing ... The FDA approval is based on the SIROCCO, CALIMA and ZONDA,
AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... benralizumab is “the first respiratory biologic with an eight-week maintenance dosing schedule”.
More from news
Approximately 8 fully matching, plus 25 partially matching documents found.
In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)
In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for treatment of severe uncontrolled asthma and COPD) in Japan.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...